Fully Human Antibody / TCR Platforms

BsADC Platform

Bispecific ADCs targeting dual tumor-associated antigens (TAAs) enhance cancer treatment by overcoming drug resistance, improving tumor specificity, boosting internalization for better tumor killing, and ensuring stronger, longer-lasting effects in heterogeneous tumors.
  • 20+
    BsADC Assets
  • 200+
    TAA Antibody Backbones
Request Data Package Schedule a Meeting
related resource

on this page

  • Advantages of Biocytogen's BsADC Platform
  • Discovery of Novel BsADCs:
  • Off-the-shelf TAA-targeting Antibodies Available for Flexible Plug & Play

Webinars

View All

    Posters

    View All
      Advantages of Biocytogen's Novel bsADC Platform
      • RenLite-derived common light chain antibodies are easy to assemble into BsAb with low mismatch rate and ideal physiochemical properties.
      • Combined with target gene knockout strategy, RenLite KO mice can generate antibodies with increased diversity, potentially against novel epitopes and with cross-species reactivity.
      • Proprietary linker/payload system BLD1102
      • Rapid generation of high-quality BsAbs/BsADCs for high-throughput in vitro and in vivo screening
      Advantages of Biocytogen's Novel bsADC Platform
      Novel linker/payload system BLD1102 independently developed by Biocytogen

      Briefly, BLD1102 is a new ADC platform developed by Biocytogen independently.

      • BCPT02 is a novel topoisomerase 1 inhibitor with broad-spectrum and potent tumor killing ability.
      • The uniquely designed cleavable linker has excellent hydrophilicity, making ADCs as hydrophilic as monoclonal antibodies, greatly improving ADC's physiochemical properties.
      • BLD1102-ADCs exhibit good stability in plasma and more potent tumor killing compared to vcMMAE.
      • BLD1102 demonstrated good tolerabilities in preclinical non-human primates.
      Biocytogen's RenLite-based BsADC Platform

      BsADC developed from RenLite mice

      BsADC developed from RenLite mice
      Discovery of Novel BsADCs:

      As part of Biocytogen's Project Integrum, combinations of TAA-targeting antibodies generated from RenLite mice are subsequently assembled and evaluated in vivo for pharmacologic efficacy, and subjected to in vitro analyses. The company's large animal translational platform will further screen out products with better translational properties:

      Off-the-shelf TAA-targeting Antibodies Available for Flexible Plug & Play
      View More
      30+ BsADC Programs Available for Partnership
      Target(s) Immunization
      • Discovery
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      PTK7 x EGFR (BCG017)
      		Preclinical
      HER3 x EPCAM (BCG044)
      		Preclinical
      B7-H4 x B7-H4 (BCG040)
      		Preclinical
      B7-H3 x MUC1 (BCG041)
      		Preclinical
      PTK7 x TROP2 (BCG033)
      		Preclinical
      FOLR1 x MUC1 (BCG023)
      		Preclinical
      DLL3 x B7-H3 (BCG025)
      		Preclinical
      DLL3 x SEZ6 (BCG030)
      		Preclinical
      TPBG x MUC1 (BCG016)
      		Candidate Selection
      TROP2 x NECTIN-4 (BCG039)
      		Candidate Selection
      CDH17 x MET
      		Candidate Selection
      B7-H4 x EPCAM
      		Candidate Selection
      B7-H4 x HER3
      		Candidate Selection
      MUC1 x B7-H4
      		Candidate Selection
      TROP2 x B7-H4
      		Candidate Selection
      FOLR1 x FOLR1
      		Candidate Selection
      FAP x GPC1 (BCG026)
      		Candidate Selection
      MUC1 x TROP2 (BCG045)
      		Candidate Selection
      MSLN x CDH3
      		Candidate Selection
      MET x CDH3
      		Leads Selection
      MET x EPCAM
      		Leads Selection
      MET x B7-H3
      		Leads Selection
      FAP x B7-H3
      		Leads Selection
      CDH6 x FOLR1
      		Leads Selection
      MUC16 x FOLR1
      		Leads Selection
      EGFR x ITGB6
      		Leads Selection
      CD142 x NECTIN-4
      		Leads Selection
      MUC16 x FOLR1
      		Leads Selection
      CDCP1 x B7-H3
      		Leads Selection
      CDH3 x EGFR
      		Leads Selection
      CLEC12A x CD33
      		Leads Selection
      10+ ADC Programs Available for Partnership
      Target(s) Immunization
      • Discovery
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      CDH3 (BCG014)
      		CMC
      ITGB6 (BCG018)
      		CMC
      ADAM9 (BCG029)
      		Candidate Selection
      TM4SF5 (BCG015)
      		Candidate Selection
      PALP (BCG037)
      		Candidate Selection
      FOLR1(nano) (BCG047)
      		Candidate Selection
      DLL3(nano)
      		Candidate Selection
      CLDN1
      		Candidate Selection
      MSLN
      		Candidate Selection
      HHLA2
      		Leads Selection
      CDCP1 (BCG046)
      		Leads Selection
      EPHA5
      		Leads Selection
      CLDN4
      		Leads Selection
      CLDN3
      		Hits Selection